SCHEMBL7032178

SCHEMBL7032178

Cc1ccccc1C(=S)c1ccc(Nc2ccccn2)cc1Cl

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 10/20 0.49
MAPK13 O15264 9/20 0.49
MAPK12 P53778 9/20 0.49
MAPK11 Q15759 9/20 0.49
GRM4 Q14833 1/20 0.46
RAB9A P51151 5/20 0.44
NPSR1 Q6W5P4 2/20 0.44
NPC1 O15118 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
THRB P10828 1/20 0.42
MAPT P10636 1/20 0.42
ALOX12 P18054 1/20 0.40
CCNK O75909 1/20 0.40
CCNA2 P20248 1/20 0.40
CDK2 P24941 1/20 0.40
CCND3 P30281 1/20 0.40
CDK9 P50750 1/20 0.40
CDK6 Q00534 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7036690 0.93 MAPK14 (0.49) MAPK14MAPK13MAPK12MAPK11GRM4
SCHEMBL7033514 0.88 MAPK14 (0.51) MAPK14MAPK13MAPK12MAPK11GRM4
SCHEMBL7036631 0.87 RAB9A (0.46) MAPK14MAPK13MAPK12MAPK11GRM4
SCHEMBL7039968 0.85 MAPK14 (0.69) MAPK14MAPK13MAPK12MAPK11GRM4
SCHEMBL7038383 0.84 MAPK14 (0.47) MAPK14MAPK13MAPK12MAPK11GRM4
SCHEMBL7040514 0.83 MAPK14 (0.47) MAPK14MAPK13MAPK12MAPK11GRM4
SCHEMBL7033588 0.82 MAPK14 (0.57) MAPK14MAPK13MAPK12MAPK11GRM4
SCHEMBL1901734 0.82 MAPK14 (0.71) MAPK14MAPK13MAPK12MAPK11NPSR1
SCHEMBL7039286 0.81 RAB9A (0.46) MAPK14MAPK13MAPK12MAPK11GRM4
SCHEMBL7037212 0.81 MAPK14 (0.52) MAPK14MAPK13MAPK12MAPK11GRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6432962-B2 Benzophenones as inhibitors of IL-1β and TNF-α LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) 2002-08-13 US claimed
EP-1289958-A2 BENZOPHENONES AS INHIBITORS OF IL-1$g(b) AND TNF-$g(a) Leo Pharma A/S (DK) 2003-03-12 EP disclosed
US-6432962-B2 Benzophenones as inhibitors of IL-1β and TNF-α LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) 2002-08-13 US disclosed
US-20020016347-A1 Benzophenones as inhibitors of IL-1beta and TNF-alpha LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) 2002-02-07 US disclosed
WO-2001090074-A2 BENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) LEO PHARMA A/S (DK) 2001-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020016347-A1 Benzophenones as inhibitors of IL-1beta and TNF-alpha IL1B, IL1A, NFKBIA MAPK14 625/4885MAPK13 1908/4885MAPK12 1184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.